Aadibio provides a cloud‑native platform that centralizes bio‑informatics pipelines, data storage, and collaborative workspaces for life‑science and biotech organizations. The platform automates routine analyses, offers version‑controlled datasets, and integrates with LIMS and major cloud services, enabling scalable, reproducible workflows and interactive visualizations for genomics, proteomics, and cell‑based assays.

The startup develops small molecule therapeutics that selectively disrupt hunger signaling to regulate energy homeostasis, providing an oral treatment for obesity and rare genetic metabolic diseases. This approach enables effective management of obesity-related conditions while preserving nutrient absorption, offering a safe therapeutic option for clinicians.

Accuragen provides a cloud‑based genomics platform that automates the full sequencing workflow, from library preparation to bioinformatics analysis, delivering high‑throughput, high‑quality DNA data. The service offers secure, HIPAA‑compliant storage, web‑portal and API access, and scalable pricing for research labs, clinical genetics centers, and pharmaceutical R&D teams, eliminating the need to manage complex sequencing infrastructure.

ACELYRIN is a late-stage clinical biopharma company focused on the development of therapies targeting unmet medical needs in immunology, specifically through the advancement of izokibep and lonigutamab for conditions like non-infectious non-anterior uveitis and thyroid eye disease. By accelerating the clinical trials and commercialization processes, ACELYRIN aims to deliver transformative treatments that improve patient outcomes and quality of life.

Adaptive Biotechnologies provides a CLIA‑certified, NGS‑based minimal residual disease assay (clonoSEQ) with sensitivity to 10⁻⁶ and high‑coverage T‑cell and B‑cell receptor immunosequencing that generates >10⁶ clonotypes per sample. The resulting repertoire data are processed through proprietary bioinformatics pipelines and delivered via secure cloud dashboards and API endpoints for clinical laboratories, trial sponsors, and biopharma drug‑discovery programs.

Adela develops a blood test platform that detects minimal residual disease (MRD) and monitors treatment response across various cancer types. This technology enables early identification and management of cancer, addressing the critical need for effective monitoring and recurrence prediction in oncology care.

Alpine Immune Sciences provides a protein‑engineering platform that creates bifunctional and multivalent therapeutics to simultaneously target multiple immune checkpoints. By combining computational design, modular scaffolds, and high‑throughput functional screening, it generates precision immunotherapies with controlled geometry and valency for oncology and autoimmune indications, enabling pharma partners to develop more specific and potent immune‑modulating drugs.

AnHeart Therapeutics is developing precision oncology therapeutics, including Taletrectinib for ROS1-positive non-small cell lung cancer and Safusidenib for IDH1-mutant gliomas and cholangiocarcinoma, both currently in Phase 2 clinical trials. The company targets specific genetic mutations in tumors to improve treatment efficacy and patient outcomes in cancer care.

Arcus Biosciences develops combination therapies using differentiated small molecules and antibodies to enhance treatment efficacy for various cancers. The company focuses on optimizing biologic mechanisms to improve patient outcomes and accelerate the delivery of new cancer therapies through global clinical trials.

Ark Biosciences discovers and develops small‑molecule, antibody, and Fc‑conjugate therapeutics for unmet respiratory, fibrotic, and pediatric neurodevelopmental diseases such as RSV, IPF, COPD, and ADHD. Leveraging proprietary platforms and global partnerships, the company advances first‑in‑class or best‑in‑class candidates—including oral RSV inhibitors, monoclonal antibodies, anti‑fibrotic agents, and long‑acting antiviral conjugates—through pre‑clinical and clinical stages to provide safer, more effective treatment options.

BeyondSpring Pharmaceuticals is developing Plinabulin, a first‑in‑class small‑molecule immune modulator that activates GEF‑H1 and reversibly binds tubulin to promote dendritic cell maturation and robust T‑cell priming. Clinical data across multiple solid‑tumor indications, including NSCLC, show improved overall survival, reduced chemotherapy‑induced neutropenia, and high disease‑control rates when combined with radiation or PD‑1/PD‑L1 inhibitors. The company targets oncology developers seeking a novel agent to enhance combination regimens and deliver a more balanced efficacy‑safety profile for cancer patients.

Cellares develops the Cell Shuttle™, a modular, cGMP platform that automates cell therapy manufacturing using a closed, single-use cartridge system. This technology increases productivity by tenfold and reduces costs by up to 50% compared to conventional contract development and manufacturing organizations (CDMOs), while also minimizing process failure rates.

CG Oncology develops Cretostimogene, an intravesically delivered oncolytic immunotherapy for non‑muscle invasive bladder cancer (NMIBC). The therapy uses a genetically engineered virus to directly lyse tumor cells and stimulate a systemic immune response, aiming to reduce recurrence and preserve the bladder. It is being evaluated in a comprehensive clinical program for safety and efficacy, targeting urologists, oncologists, and healthcare systems seeking bladder‑sparing treatments.

Conjugatebio provides contract development and manufacturing services for conjugated biologics, including antibody‑drug conjugates. Leveraging proprietary conjugation platforms and a GMP‑certified facility, it offers end‑to‑end support from molecular design and chemistry optimization to scale‑up production, analytical characterization, and regulatory documentation for pharma and biotech partners.

The startup develops protein analysis software that utilizes reverse-translation technology to convert peptide sequences into DNA, enabling single-molecule protein sequencing. This platform provides researchers with complete proteome information at scale, facilitating more efficient protein sample analysis.

Equillium develops Itolizumab, a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells in severe autoimmune and inflammatory disorders. The company also utilizes a proprietary multi-cytokine inhibitor platform to address the unmet medical needs associated with various inflammatory conditions.

Everest Medicines is a biopharmaceutical company focused on the discovery and development of novel pharmaceutical therapies and vaccines to meet critical unmet medical needs in Greater China and the Asia Pacific region. Their pipeline includes treatments for conditions such as IgA nephropathy and primary membranous nephropathy, aiming to improve patient outcomes through targeted therapeutic interventions.

Firefly Bio develops Degrader Antibody Conjugates (DACs) by integrating selective protein degraders with the capabilities of traditional ADCs. Their proprietary platform enables the highly specific delivery of these novel degraders directly to target tissues. This technology allows for the scalable access and utilization of new classes of ADC payloads.

Grail develops the Galleri® test, a multi-cancer early detection (MCED) blood test that analyzes DNA methylation patterns to identify signals from various cancers that lack standard screening methods. This technology enables earlier cancer detection, potentially improving treatment outcomes and reducing mortality rates.

GRIT Biotechnology develops tumor-infiltrating lymphocyte (TIL) immunotherapy specifically for solid tumors, utilizing a proprietary method to expand and activate patients' own immune cells for targeted cancer treatment. This approach addresses the challenge of tumor heterogeneity and enhances the safety and efficacy of cancer therapies by leveraging the body's natural immune response.

Harton is a biotechnology platform that develops personalized immune therapies through scalable cell manufacturing processes, targeting the unique immune profiles of individual patients. This approach addresses the limitations of traditional one-size-fits-all treatments by providing tailored therapies that enhance patient outcomes in healthcare.

Hummingbird Bioscience develops next-generation antibody-drug conjugates (ADCs) using proprietary linker-payload technologies to target cancer cells with high specificity. Their approach aims to provide effective treatment options for patients who do not respond to existing therapies, enhancing the potential for durable clinical responses.

ImmPACT Bio USA is developing logic-gated CAR T cell therapies that prevent antigen escape and rewire T cell responses to overcome the immunosuppressive tumor microenvironment in cancer. Their technology aims to enhance the specificity of T cell targeting, enabling effective treatment of solid tumors while sparing normal tissue.

Insight Lifetech manufactures interventional cardiovascular diagnostic and therapy products that enhance precision in diagnosing and treating cardiovascular diseases. Their technology focuses on advanced medical imaging and therapeutic solutions, addressing the need for reliable tools in the management of heart health.